Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.

A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry. 1993 May 15; 33(10):700-6.

View in: PubMed

© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.